The Resveratrol Disappointment: A Decade of Failed Promises
Resveratrol is a red-wine and grape compound that drew enormous investment after early studies suggested it could switch on the SIRT1 enzyme and extend lifespan, but more than two decades later it has delivered almost none of that promise in people. The foundational science came apart when independent labs showed the apparent SIRT1 activation was an artefact of a fluorescent tag used in the test tube, and pooled human trials have generally failed to show lasting gains in blood sugar, blood pressure, or body composition — even in patients with diabetes or heart-disease risk. The compound is also poorly absorbed, broken down so fast in the gut and liver that very little reaches the bloodstream intact. The practical takeaway is that a striking result in yeast or mice is not evidence it will work in humans, and resveratrol is the textbook example.
The Promising Start
The story began with Howitz et al. 2003 in Nature (from David Sinclair's lab), showing that resveratrol activated yeast Sir2p and extended yeast replicative lifespan. Baur et al. 2006 in Nature reported that resveratrol improved health and survival in middle-aged mice fed a high-calorie diet. The biotech company Sirtris was founded on this work and was acquired by GlaxoSmithKline for about $720 million in 2008 to develop sirtuin-activating compounds as drugs. Resveratrol supplement sales soared.
Did the mouse result ever translate?
Where It Fell Apart
The mechanistic story unravelled when independent labs showed that resveratrol's apparent SIRT1 activation depended on a fluorescent peptide tag used in early in-vitro assays. Pacholec et al. 2010 in the Journal of Biological Chemistry demonstrated that resveratrol does not activate SIRT1 against unmodified peptide substrates; the apparent activation was an assay artefact. In 2010 GSK halted dosing in a multiple-myeloma trial of the resveratrol formulation SRT501 because of renal failure events. By 2013, GSK had folded its Sirtris stand-alone operations into its main R&D structure (some sirtuin-activator programmes continued, but the standalone effort ended). In humans, resveratrol's bioavailability is also poor — it is rapidly metabolised in the gut wall and liver to glucuronide and sulfate conjugates, leaving very low levels of the parent compound in plasma. Pooled RCT data have generally not shown durable improvements in fasting glucose, insulin sensitivity, blood pressure, or body composition, even in patients with type 2 diabetes or cardiovascular risk factors.
What We Learned
Resveratrol's story is a cautionary tale about the distance between animal-model excitement and human efficacy. Yeast, worms, and mice are not small humans. The lesson — that mechanistic elegance in a petri dish or mouse cage is not clinical evidence — is one the supplement and biotech industries continue to relearn with each new molecule.
Sources
- Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. "Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan." Nature, 2003;425(6954):191–196. PMID: 12939617. DOI: 10.1038/nature01960.
- Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. "Resveratrol improves health and survival of mice on a high-calorie diet." Nature, 2006;444(7117):337–342. PMID: 17086191. DOI: 10.1038/nature05354.
- Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K. "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1." Journal of Biological Chemistry, 2010;285(11):8340–8351. PMID: 20061378. DOI: 10.1074/jbc.M109.088682.
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. "High absorption but very low bioavailability of oral resveratrol in humans." Drug Metabolism and Disposition, 2004;32(12):1377–1382. PMID: 15333514. DOI: 10.1124/dmd.104.000885.
- Sahebkar A. "Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials." Nutrition Reviews, 2013;71(12):822–835. PMID: 24111842. DOI: 10.1111/nure.12081.
- Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. "The therapeutic potential of resveratrol: a review of clinical trials." npj Precision Oncology, 2017;1:35. PMID: 29354782. DOI: 10.1038/s41698-017-0038-6.
Reviewed against 6 peer-reviewed sources.